Durán R, Reina G R, Hontoria J M, Merino C, Olivier C, Carballido J
Actas Urol Esp. 1989 Jan-Feb;13(1):19-23.
A retrospective study was done on the long-term evolution of 48 patients diagnosed of transitional cell carcinoma of the bladder who were treated with full transurethral resection and intracavitary chemoprophylaxis with Thiotepa. All patients presented a minimum disease control period of 36 months, and were followed for 85.3 months on the average (38-156) months. The actuarial study of the relapse-free intervals turned out into a possibility of 89.3% of patients without a relapse by 5 years, and of 64.6% by 10 years. The actuarial study of tumor progress showed that 91.4% and 58.8% of the patients were free of progression by 5 and 10 years respectively. pT1-G3 tumors did not show greater relapse rate nor progression than the rest of cases, it is therefore convenient to consider other prognostic factors in the long-term evolution of these patients. 85.7% of patient deaths were due to direct consequence of the bladder tumor. These results and their clinical implications are analyzed.